Yahoo Finance Appili Therapeutics Full Year 2023 Earnings: CA$0.081 loss per share (vs CA$0.38 loss in FY 2022)
Appili Therapeutics (TSE:APLI) Full Year 2023 Results
Key Financial Results
Revenue: CA$334.2k (down 76% from FY 2022).
Net loss: CA$9.24m (loss narrowed by 63% from FY 2022).
CA$0.081 loss per share (improved from CA$0.38 loss in FY 2022).
APLI Products In Clinical Trials
Phase I: 1.
Phase III: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Appili Therapeutics Earnings Insights
Looking ahead, revenue is expected to decline by 150% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Canada are expected to grow by 13%.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are down 14% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 7 warning signs for Appili Therapeutics (6 are potentially serious!) that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
